Microrna and uses thereof in prevention and/or treatment of fibroplasia medical sign and/or syndrome

1. A method of preventing and/or treating a fibrotic disease and/or syndrome comprising administering to a subject in need thereof a polynucleotide, wherein the polynucleotide comprises a sequence set forth in SEQ ID NO: 8, or a complementary sequence thereof.

2. The method according to claim 1 , wherein the fibrotic disease and/or syndrome is a fibrotic disease and/or syndrome of the lung.

3. The method according to claim 1 , wherein the fibrotic disease and/or syndrome is selected from the group consisting of

silicosis, asbestosis, anthracosis, farmer's lung, air-conditioner lung, pigeon-breeder's lung, bagassosis, and familial pulmonary fibrosis.

4. The method according to claim 1 , further comprising administering an additional anti-fibrotic agent separately and/or together, temporally and/or spatially, to the subject in need thereof.

5. The method according to claim 4 , wherein the additional anti-fibrotic agent is one or more selected from the group consisting of: a glucocorticoid, beclomethasone; an immunosuppressive agent; an antioxidant; an anticoagulant; and colchicine, interferon, ACEI and a statin.

6. The method according to claim 1 , wherein the polynucleotide is a small RNA.

7. The method according to claim 1 , wherein the polynucleotide is synthetic or expressed from an artificial vector.

8. The method according to claim 5 , wherein the glucocorticoid is cortisone acetate, hydrocortisone, prednisolone, dexamethasone, betamethasone, triamcinolone, triamcinolone acetonide, or beclomethasone.

9. The method according to claim 5 , wherein the immunosuppressive agent is cyclophosphamide, azathioprine, or methotrexate.

10. The method according to claim 5 , wherein the antioxidant is acetylcysteine, carbocisteine.

11. The method according to claim 5 , wherein the anticoagulant is low molecular weight heparin.